• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喷雾干燥立方脂质体并用卵清蛋白和 Quil-A 作为纳米干粉疫苗制剂。

Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation.

机构信息

Department of Micro- and Nanotechnology, Technical University of Denmark, Oersteds Plads 345C, 2800 Kgs. Lyngby, Denmark.

School of Pharmacy, University of Otago, Frederick Street 18, Dunedin 9054, New Zealand.

出版信息

Int J Pharm. 2018 Oct 25;550(1-2):35-44. doi: 10.1016/j.ijpharm.2018.08.036. Epub 2018 Aug 19.

DOI:10.1016/j.ijpharm.2018.08.036
PMID:30134183
Abstract

Subunit vaccine formulations are often produced as liquid dispersions through complicated processes. It is desirable, however, to have simple, cheap and up-scalable methods to produce nanoparticulate subunit vaccines in powder form. Here, a simple single-step spray drying process for production of powder cubosome precursors with the model antigen ovalbumin (OVA) and the adjuvant Quil-A is presented. The cubosomes were characterized in vitro and evaluated in vivo by subcutaneous and oral administration for their potential as a vaccine formulation. Hydrated cubosomes had average particle size of 257 ± 8 nm and zeta potential of -18.0 ± 0.6 mV. The powder contained 10.6 ± 0.7% w/w OVA prior to hydration, of which 65 ± 1% was released within the first 20 min in 9.5 mM PBS at pH 7.3, with the remaining OVA gradually released over the following 24 h. Immunization with cubosomes resulted in significantly stronger antigen-specific serum IgG responses (p < 0.01), CD8 T cell expansion (p < 0.0001) and target T cell killing compared to controls when given s.c., and was ineffective orally. This study shows that spray drying is a suitable method for producing nanoparticulate vaccine formulations in dry powder form.

摘要

亚单位疫苗制剂通常通过复杂的工艺制成液体分散体。然而,人们希望有一种简单、廉价且可扩展的方法来生产粉末形式的纳米亚单位疫苗。本研究介绍了一种简单的单步喷雾干燥工艺,用于生产包载模型抗原卵清蛋白(OVA)和佐剂 Quil-A 的立方相纳米脂质体前体。对立方相纳米脂质体进行了体外表征,并通过皮下和口服途径进行了体内评价,以评估其作为疫苗制剂的潜力。水合立方相纳米脂质体的平均粒径为 257±8nm,zeta 电位为-18.0±0.6mV。粉末在水合之前含有 10.6±0.7%w/w OVA,其中 65±1%在 pH 7.3 的 9.5mM PBS 中在前 20 分钟内释放,其余 OVA 在随后的 24 小时内逐渐释放。与对照组相比,当通过皮下途径给予立方相纳米脂质体时,可显著增强抗原特异性血清 IgG 应答(p<0.01)、CD8 T 细胞扩增(p<0.0001)和靶 T 细胞杀伤,而口服途径则无效。本研究表明,喷雾干燥是一种适用于生产干粉形式的纳米疫苗制剂的方法。

相似文献

1
Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation.喷雾干燥立方脂质体并用卵清蛋白和 Quil-A 作为纳米干粉疫苗制剂。
Int J Pharm. 2018 Oct 25;550(1-2):35-44. doi: 10.1016/j.ijpharm.2018.08.036. Epub 2018 Aug 19.
2
Microcontainers as an oral delivery system for spray dried cubosomes containing ovalbumin.微容器作为含卵清蛋白的喷雾干燥立方液晶脂质体的口服给药系统。
Eur J Pharm Biopharm. 2017 Sep;118:13-20. doi: 10.1016/j.ejpb.2016.12.008. Epub 2016 Dec 18.
3
Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).重组干燥粉末制剂的 ZnO 佐剂卵清蛋白诱导的抗原特异性抗体与用 Alhydrogel®或阳离子佐剂制剂 01(CAF®01)佐剂的卵清蛋白相当,但 T 细胞反应较低。
Int J Pharm. 2023 Dec 15;648:123581. doi: 10.1016/j.ijpharm.2023.123581. Epub 2023 Nov 4.
4
A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.喷雾干燥和喷雾冷冻干燥生产吸入用流感亚单位疫苗粉末的比较。
J Control Release. 2010 Jun 1;144(2):127-33. doi: 10.1016/j.jconrel.2010.02.025. Epub 2010 Feb 25.
5
Evaluation of the effects of spray drying parameters for producing cubosome powder precursors.喷雾干燥参数对 cubosome 粉体前体的影响评价。
Eur J Pharm Biopharm. 2019 Feb;135:44-48. doi: 10.1016/j.ejpb.2018.12.008. Epub 2018 Dec 18.
6
Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.设计 CAF 佐剂干粉疫苗:喷雾干燥法保持 CAF01 的佐剂活性。
J Control Release. 2013 May 10;167(3):256-64. doi: 10.1016/j.jconrel.2013.01.031. Epub 2013 Feb 8.
7
Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.免疫原性和物理评估作为喷雾干燥粉末制剂的多阶段结核亚单位候选疫苗 H56/CAF01。
Vaccine. 2018 May 31;36(23):3331-3339. doi: 10.1016/j.vaccine.2018.04.055. Epub 2018 Apr 24.
8
Development of (Inhalable) Dry Powder Formulations of AS01-Containing Vaccines Using Thin-Film Freeze-Drying.采用薄膜冷冻干燥法开发含 AS01 的(可吸入)干粉制剂疫苗。
Int J Pharm. 2022 Jun 25;622:121825. doi: 10.1016/j.ijpharm.2022.121825. Epub 2022 May 13.
9
Preparation and Characterization of an Oral Vaccine Formulation Using Electrosprayed Chitosan Microparticles.采用电喷法制备壳聚糖微球口服疫苗制剂及特性分析。
AAPS PharmSciTech. 2018 Nov;19(8):3770-3777. doi: 10.1208/s12249-018-1190-1. Epub 2018 Oct 2.
10
Microcontainers for protection of oral vaccines, in vitro and in vivo evaluation.微容器用于保护口服疫苗的体外和体内评价。
J Control Release. 2019 Jan 28;294:91-101. doi: 10.1016/j.jconrel.2018.11.030. Epub 2018 Dec 12.

引用本文的文献

1
Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems.液晶纳米颗粒作为药物递送系统的研究进展
Pharmaceutics. 2023 May 6;15(5):1421. doi: 10.3390/pharmaceutics15051421.
2
A Synoptic Update on Smart Lipid Nanocarrier: Cubosomes, and their Design Development, and Recent Challenges.智能脂质纳米载体:立方脂质体及其设计开发的综合更新,以及近期面临的挑战。
Curr Pharm Biotechnol. 2024;25(4):434-447. doi: 10.2174/1389201024666230519103330.
3
In vitro Evaluation of Paliperidone Palmitate Loaded Cubosomes Effective for Nasal-to-Brain Delivery.
棕榈酸帕利哌酮载入立方液晶纳米载体的体外评价-对鼻内递送到脑内有效。
Int J Nanomedicine. 2023 Mar 1;18:1085-1106. doi: 10.2147/IJN.S397650. eCollection 2023.
4
Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit.纳米载体辅助经口腔和鼻腔粘膜途径的无针疫苗递送:一种新型治疗途径
Front Pharmacol. 2022 Jan 11;12:757761. doi: 10.3389/fphar.2021.757761. eCollection 2021.
5
Demystifying particle-based oral vaccines.解析基于粒子的口服疫苗。
Expert Opin Drug Deliv. 2021 Oct;18(10):1455-1472. doi: 10.1080/17425247.2021.1946511. Epub 2021 Jul 6.
6
Targeted Antitumor Mechanism of C-PC/CMC-CD55sp Nanospheres in HeLa Cervical Cancer Cells.C-PC/CMC-CD55sp纳米球对HeLa宫颈癌细胞的靶向抗肿瘤机制
Front Pharmacol. 2020 Jun 18;11:906. doi: 10.3389/fphar.2020.00906. eCollection 2020.